ReviewDrug metabolism and disposition: the biological fate of chemicals2026
The regulatory potential of cytochrome P450-adrenodoxin interactions: Insights toward understanding redox partner regulation in drug metabolizing enzymes.
Review in Drug metabolism and disposition: the biological fate of chemicals, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Mitochondrial cytochrome P450 enzymes perform critical functions in steroidogenic, vitamin D, and vitamin A pathways. Their function relies on the formation of a redox complex with the soluble ferredoxin protein adrenodoxin (Adx). Mounting evidence indicates that cytochromes P450 (P450)-Adx interactions are highly context-dependent and are shaped by proximal P450 surface architecture and substrate occupancy within the active site. Although the core electron-transfer geometry is conserved across mitochondrial P450s, subtle differences at the interface and conformational adjustments allow the system to fine-tune electron delivery to support the distinct structural, mechanistic, and catalytic requirements of each enzyme. This role establishes Adx as an effector molecule in addition to an electron donor. This minireview surveys recent developments in our understanding of P450-Adx complexes, with particular attention drawn to differences in the P450 proximal surfaces. We also discuss these insights as a new framework for understanding analogous complexes in the microsomal P450s, which are important in drug metabolism. SIGNIFICANCE STATEMENT: Recent advancements in the study of P450-adrenodoxin complexes highlight the role of adrenodoxin as an effector molecule. This review seeks to contextualize these developments from the perspective of both potential therapeutics and lessons learned regarding drug metabolizing P450-redox partner protein complexes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.